Shiv Sarin to Hepacivirus
This is a "connection" page, showing publications Shiv Sarin has written about Hepacivirus.
Connection Strength
0.997
-
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease. Liver Int. 2018 12; 38(12):2137-2148.
Score: 0.363
-
Point -of -care testing (POCT) in molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection. J Clin Virol. 2017 03; 88:46-51.
Score: 0.332
-
Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol. 2006 Apr; 78(4):452-8.
Score: 0.157
-
Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. Hepatol Int. 2019 Mar; 13(2):173-179.
Score: 0.096
-
APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int. 2019 Nov; 13(6):649-661.
Score: 0.025
-
APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Hepatol Int. 2019 Mar; 13(2):103-109.
Score: 0.024